Compare DKS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DKS | RPRX |
|---|---|---|
| Founded | 1948 | 1996 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 19.4B |
| IPO Year | 2002 | 2020 |
| Metric | DKS | RPRX |
|---|---|---|
| Price | $202.72 | $45.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $241.50 | $47.75 |
| AVG Volume (30 Days) | 923.4K | ★ 3.8M |
| Earning Date | 02-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.39% | 2.07% |
| EPS Growth | ★ 15.35 | N/A |
| EPS | ★ 8.66 | 1.78 |
| Revenue | ★ $13,442,849,000.00 | $2,378,193,000.00 |
| Revenue This Year | $30.99 | $39.10 |
| Revenue Next Year | $26.26 | $5.02 |
| P/E Ratio | ★ $23.56 | $25.37 |
| Revenue Growth | 3.53 | ★ 5.06 |
| 52 Week Low | $166.37 | $29.66 |
| 52 Week High | $237.31 | $46.14 |
| Indicator | DKS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 72.73 |
| Support Level | $198.00 | $42.50 |
| Resistance Level | $207.31 | $46.14 |
| Average True Range (ATR) | 6.43 | 1.01 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 28.55 | 80.80 |
Dick's Sporting Goods is a retailer that offers sports and outdoor apparel, footwear, and equipment online and in physical stores. The company's legacy business includes more than 700 stores under its own name, more than 110 Golf Galaxy golf specialty stores, and about 50 outlet stores. In September 2025, Dick's acquired multinational retailer Foot Locker. With this move, Dick's added about 2,600 stores under the Foot Locker, Kids Foot Locker, Champs Sports, atmos, and WSS nameplates in North America, the Asia-Pacific, and EMEA—Europe, the Middle East, and Africa. Based in the Pittsburgh area, Dick's was founded in 1948 by the father of current executive chair and controlling shareholder Edward Stack.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.